Starting a GLP-1

The basics: you will want to discuss a few important things with your GLP-1 prescriber, you will begin well below your target dose and work up to it over months, the weight loss and side effects might be less significant than you initially expect, and there are a few steps you should take to maximize your health when taking a GLP-1.

Who can take a GLP-1, and what should you sort out first?

A few things are easier to sort out before your first dose than after it.

Whether you can take one. Four drugs are approved for chronic weight management: Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Foundayo (orforglipron, approved in April 2026, the first pill approved for weight management). The labels describe who they’re for in words rather than numbers: adults with obesity, or adults who are overweight and have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. In practice, clinicians and insurers apply the thresholds the trials used: a BMI of 30 or higher, or 27 or higher with one of those conditions. Wegovy and Saxenda are also approved for adolescents aged 12 and up.

Ozempic, Mounjaro, and Rybelsus are approved for type 2 diabetes, not for weight management. They are widely prescribed for weight anyway, which is called off-label prescribing. It is legal and common, and which one you have been offered affects what your insurer is willing to cover.

Both weight-management approvals are written as paired with a reduced calorie diet and more physical activity. That wording matters: the food and movement side is part of the treatment as approved, not an optional extra someone added later. Your prescriber will also screen you for reasons not to take a GLP-1.

The primary reasons you should not take a GLP-1 are if you or a close family member has had medullary thyroid cancer or a condition called MEN-2, or if you are pregnant. Beyond those, your prescriber will consider things like a history of pancreatitis, existing digestive problems, and the other medications you take. That screening is theirs to do, and it is worth bringing a full list of what medications/supplements you take to the appointment.

Who will still be following you in a year. Your GP, a doctor who specializes in weight management, and telehealth services all prescribe GLP-1s. The credential matters less than the continuity. This is a treatment you stay on, so the useful question is who will be adjusting your dose and taking your calls twelve months from now.

What you are committing to. GLP-1s work while you are taking them. In the withdrawal trials, people who stopped taking GLP-1s regained much of what they had lost within about a year, though most stayed below where they began. In practice, maintaining weight loss with GLP-1s is like managing an ongoing condition, so it is worth asking your prescriber early what staying on it looks like, and what would change about your eating and training if you ever tapered off. We go through what those withdrawal/maintenance trials actually found separately.

If you take an oral contraceptive. Tirzepatide, sold as Mounjaro and Zepbound, slows how quickly your stomach empties, which reduces how much of the pill your body absorbs. You need a backup or non-oral method for four weeks after you start, and again for four weeks after every dose increase. Foundayo (orforglipron) carries a similar instruction, but its window is 30 days, not four weeks. The semaglutide products (Ozempic, Wegovy, Rybelsus) and Saxenda carry no such instruction. Check the label for the product you are actually on, because the windows differ and are not interchangeable.

Questions worth asking your prescriber

• How long will it take to reach the full dose, and what does the schedule look like?
• What should I do if the side effects are hard to tolerate after a dose increase?
• What is the plan if I want to come off, and what should I expect if I do?
• Can you refer me to structured lifestyle support, or do I arrange that myself?
• What would make you want me to call rather than wait for the next appointment?
• Does anything in my history, or any medication I already take, change how we do this?

How much should I expect to pay for a GLP-1?

The list price is not what most people pay, and what you actually pay depends almost entirely on your coverage.

Paying cash, the manufacturers sell directly for roughly $149 to $449 a month depending on the product and the dose, well below the list prices past $1,000 that you may have seen quoted. The oral products sit at the bottom of that range and the highest injectable doses at the top. With commercial insurance and a manufacturer savings card it can come down to around $25, though those cards exclude anyone on Medicare, Medicaid, VA or TRICARE.

Coverage is where the rest of the variation lives, and it is worth sorting out before your first dose rather than after. GLP-1 insurance coverage goes through what to expect from each type of plan, including the Medicare route that opened in July 2026, what happens if you are asked for prior authorization, and how to appeal if you are turned down. Our insurance checker is the faster way to find where your own plan stands.

These figures are current as of 2026 and change frequently, so confirm them before you commit to anything.

What happens in the first few weeks of taking a GLP-1?

You start below the dose that does the work and climb toward it over months. That is why the first stretch can feel like not much is happening.

Most people describe the early weeks as mild rather than dramatic. You may notice you are full sooner, or that you stop halfway through a meal you would normally finish. The scale often does not move much yet. None of that means it is not working, and it is not a reason to ask for a faster increase.

The dose climbs a fixed ladder. Each step is held for about four weeks before going higher. Wegovy (semaglutide) climbs through five steps and takes at least sixteen weeks to reach its 2.4 mg maintenance dose. For adults who tolerate 2.4 mg for at least four weeks and need more, the label allows an optional increase to 7.2 mg. Tirzepatide starts at 2.5 mg and moves up in 2.5 mg increments.

If yours is an injection and you have never given yourself one, how to inject a GLP-1 walks through sites, technique, and storage. Your exact schedule depends on which medication you are on: Wegovy, Zepbound, Mounjaro, Ozempic, or Rybelsus. If you are not sure which one you have been prescribed, the box will give the brand name and the molecule underneath it.

Not all of them are injections, and how you take it matters. Rybelsus is semaglutide as a daily tablet, and it comes with timing rules the injections do not have: it has to be taken fasting, with only a sip of water, and you wait before eating or taking anything else. Very little of an oral dose survives the trip through your gut even when you do it correctly, so the instructions are the difference between a working dose and a wasted one. Whichever you are prescribed, read the instructions that come with it and follow them exactly. They change, and your pharmacist can confirm the current version.

The first change most people notice is not on the scale. Most people register something within the first two to four weeks, and it is usually appetite rather than weight. Appetite drops, and the constant background chatter about food gets quieter, often within the first few weeks. That quieting is how GLP-1s actually work doing its job. People tend to register that before any change in weight, and it is a reasonable sign the medication is doing something.

Weight comes off gradually, and how much varies a great deal. Most of it arrives at the higher doses. In the two-year STEP 5 trial of semaglutide 2.4 mg, about 52 percent of participants lost at least 15 percent of their body weight, and about 36 percent lost at least 20 percent. A meaningful number lost less. There is no reliable way to know in advance what you will experience, so it is worth holding your own expectations loosely for the first few months and judging by how you feel rather than against someone else’s result.

Side effects cluster early, and again after each increase. They usually ease as your body adjusts. That pattern is worth expecting, because a rough week after a dose step is the point at which people most often decide the drug is not for them.

How do you manage side effects?

Most stomach side effects are manageable. The two things that help most are how fast you move up the dose ladder and how you eat.

Nausea, constipation, and feeling full much sooner than you expect are the common ones. They are also the leading reason people stop taking these drugs, which is why it is worth having a plan before they show up rather than after.

What clinicians consistently recommend:

• Eat smaller portions than you think you need.
• Stop at the first sign of fullness rather than finishing what is in front of you.
• Eat slowly. Fullness registers late, so it is easy to overshoot before you notice.
• Ease off very fatty and spicy food while your body is adjusting.
• Keep fluids up, especially if you are dealing with constipation.

These come from clinical experience rather than from a trial that tested them head to head. They are still what most prescribers will tell you, and they cost nothing to try. If they are not enough, we go through managing GLP-1 side effects in much more detail separately.

The bigger lever is dose pace. If a dose increase leaves you genuinely unwell, staying at your current dose longer is a normal adjustment, not a failure or a setback. Going up more slowly is exactly what the dose ladder is for. It is standard practice and what prescribers consistently recommend, though how much dose timing changes tolerability has not been well studied. If a dose increase is making you miserable, tell your prescriber before you decide the medication is not for you.

When should you call your prescriber?

Some things are not the ordinary adjustment, and the full picture is on our GLP-1 safety page. Call your prescriber if you have:

• Vomiting that is severe, or that will not stop
• Trouble keeping fluids down
• Severe pain in your belly, especially pain that spreads to your back

What should you do to maximize health and success with a GLP-1?

The months while your dose is still climbing are the best time to start looking after the rest of your health, because what you build now carries through the weight loss that follows.

Ask to be referred to real lifestyle support. The US Preventive Services Task Force recommends that every adult with obesity be offered or referred to structured counseling covering food, activity, and behavior change, and a 2025 four-society expert advisory says the same. In practice it rarely reaches people: take-up of the Medicare benefit that pays for exactly this counseling runs under 1%. It is also worth knowing that the weight-loss figures from the big trials came from programs that included exactly this kind of support alongside the drug. Asking for a referral is a reasonable request, and it is the single most useful thing on this list that costs you nothing.

Get enough protein. During weight loss, most clinicians work from a target of roughly 80 to 120 grams a day. The 2025 expert advisory on GLP-1 care describes targets in that range as proposed rather than settled, and much of the underlying research was funded by companies that sell protein. It is still the number most clinicians use. One caveat worth raising at your appointment: every study behind it was run in people with normal kidney function, so if you have kidney disease the right target is a question for the clinician managing it. We grade the evidence behind that number separately. Eating less overall makes what you do eat count for more, which is its own question about what to eat.

Lift something heavy, regularly. Resistance training reduces how much muscle you lose while dropping weight. It is the most reliable thing you can do to hold onto muscle while losing weight.

The reason both of those matter early: the medication lowers how much you eat, and it carries nothing that protects muscle and bone while the weight comes off. Most of what you lose is fat, but some of it is muscle and bone density, and that is true of losing weight any other way too. Protecting them was never what the drug was designed to do, which leaves it as the part you can influence. We go into it more deeply in what GLP-1s do to your muscle.

Track something other than the scale. How many stairs you can climb without stopping. Whether you can carry the groceries in one trip. How far you can walk. The scale cannot tell you what kind of weight you lost, or how much quality of life you have gained, which is the thing that actually matters here.

What should you tell your other doctors?

If you have surgery, a colonoscopy, or any procedure involving anesthesia or sedation, tell that team you take a GLP-1 when you book it, not on the day. These medications slow how quickly your stomach empties, which changes how they prepare you. It is also worth mentioning to any other clinician who prescribes for you.

Sources and review

Who these drugs are approved for, and safety labeling

• US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 215256, Wegovy (semaglutide 2.4 mg injection). Approved June 4, 2021. accessdata.fda.gov
• US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 217806, Zepbound (tirzepatide). accessdata.fda.gov
• US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 209637, Ozempic (semaglutide). Approved December 5, 2017. accessdata.fda.gov
• US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 215866, Mounjaro (tirzepatide). Approved May 13, 2022. accessdata.fda.gov
• US FDA, Center for Drug Evaluation and Research. Summary Review, Rybelsus (oral semaglutide). accessdata.fda.gov

What to expect, and how much weight comes off

• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223-4226. doi:10.1172/jci78371
• Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4

Side effects and how they are managed

• Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. 2024;47(2):280-284. doi:10.2337/dc23-1791
• Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. doi:10.1080/00325481.2021.2002616

What happens if you stop

• Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
• Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414. doi:10.1001/jama.2021.3224
• Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331(1):38. doi:10.1001/jama.2023.24945

Protein, muscle, and lifestyle support

• Grosicki GJ, Dhurandhar NV, Unick JL, et al. Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications. Curr Dev Nutr. 2024;8(11):104486. doi:10.1016/j.cdnut.2024.104486
• Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023
• Eglseer D, Traxler M, Embacher S, et al. Nutrition and Exercise Interventions to Improve Body Composition for Persons with Overweight or Obesity Near Retirement Age: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2023;14(3):516-538. doi:10.1016/j.advnut.2023.04.001
• Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(4):423. doi:10.3390/nu10040423
• US Preventive Services Task Force, Curry SJ, Krist AH, et al. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults. JAMA. 2018;320(11):1163. doi:10.1001/jama.2018.13022
• Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021;325(14):1403. doi:10.1001/jama.2021.1831

Cost and coverage

• Novo Nordisk. NovoCare Pharmacy self-pay pricing for Wegovy (retrieved 2026)
• Eli Lilly. LillyDirect self-pay pricing for Zepbound (retrieved 2026)

Not yet medically reviewed. This page is in editorial review. A named clinical reviewer and review date are required before it is indexed.